US EditionPublished • loading... • Updated
Castle Biosciences, Inc. (CSTL) Stock Analysis: Unveiling A 51.85% Potential Upside With Strong Analyst Ratings
Summary by DirectorsTalk Interviews
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
Castle Biosciences, Inc. (CSTL) Stock Analysis: Unveiling A 51.85% Potential Upside With Strong Analyst Ratings
Castle Biosciences, Inc. (NASDAQ: CSTL), a prominent player in the healthcare sector, specializes in molecular diagnostics, offering innovative solutions for dermatologic cancers, Barrett’s esophagus (BE), uveal melanoma, and mental health conditions. This Friendswood, Texas-based company has carved a niche in the diagnostics and research industry by providing cutting-edge test solutions such as DecisionDx-Melanoma and MyPath Melanoma, among oth…
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
